Englewood, N.J. — Israeli biotech startup SpotitEarly has officially launched in the United States, backed by more than $20 million in funding to expand its pioneering at-home cancer detection technology. The company, which combines artificial intelligence and trained dogs to detect cancer through breath samples, has achieved a 94% accuracy rate in clinical trials, positioning itself as a potential game-changer in early cancer screening.
SpotitEarly’s approach involves analyzing volatile organic compounds (VOCs) in a user’s breath using scent-detection dogs and a proprietary AI system called LUCID, which tracks behavioral and physiological indicators from the animals. The non-invasive, at-home test is designed to detect the four most prevalent cancers—breast, colorectal, prostate, and lung—and is expected to be commercially available in the U.S. by 2026.
With the U.S. cancer care market projected to hit $245 billion by 2030, SpotitEarly’s technology could provide a much-needed, cost-effective alternative to conventional cancer screenings, which are often costly, invasive, and underutilized.
The company’s expansion is supported by a strong network of investors and advisors. Financial backers include Hanaco VC, Menomedin VC, former Timberland CEO Jeff Swartz, Wix.com CEO Avishai Abrahami, and others. SpotitEarly has also secured significant grant funding, including from the BIRD Foundation, which supports joint U.S.-Israeli innovation.
“This is a critical moment in preventive healthcare,” said Alon Lifshitz, Founding Partner at Hanaco Ventures. “SpotitEarly offers a practical and affordable solution that has the potential to dramatically increase early detection and survival rates.”
To support its U.S. operations, SpotitEarly has brought on several high-profile American medical experts, including Dr. David Sidransky, a leader in molecular cancer diagnostics; Jonathan Fleming, a senior lecturer at MIT and veteran medtech investor; and Dr. Len Lichtenfeld, former deputy Chief Medical Officer of the American Cancer Society, who now serves as SpotitEarly’s Chief Medical Officer. The company is also building partnerships with leading U.S. academic medical centers, including the University of Pennsylvania.
“Bringing SpotitEarly to the U.S. is about more than launching a product,” said CEO Shlomi Madar, Ph.D. “It’s about changing how we approach one of the most devastating diseases of our time. Our method is not only innovative—it’s accessible, scalable, and designed for real-world impact.”
Alongside its market entry, SpotitEarly has opened a Series A funding round under Regulation D, allowing accredited investors to participate in its next stage of growth.
